Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study.

Brinkmann, Christina; Abdel-Wahab, Mohamed; Bedogni, Francesco; Bhadra, Oliver D; Charbonnier, Gaetan; Conradi, Lenard; Hildick-Smith, David; Kargoli, Faraj; Latib, Azeem; Van Mieghem, Nicolas M; Miura, Mizuki; Mylotte, Darren; Landes, Uri; Pilgrim, Thomas; Riess, Friedrich-Christian; Taramasso, Maurizio; Tchétché, Didier; Testa, Luca; Thiele, Holger; Webb, John; ... (2021). Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. Catheterization and cardiovascular interventions, 98(4), pp. 756-764. Wiley-Blackwell 10.1002/ccd.29755

[img] Text
Bioprosthetic_valve_fracture.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

OBJECTIVES

To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).

BACKGROUND

BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.

METHODS

The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.

RESULTS

Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.

CONCLUSIONS

BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Pilgrim, Thomas, Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-1946

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

20 Jan 2022 11:45

Last Modified:

05 Dec 2022 15:59

Publisher DOI:

10.1002/ccd.29755

PubMed ID:

33991385

Uncontrolled Keywords:

aortic valve disease percutaneous intervention percutaneous valve therapy structural heart disease intervention transcatheter valve implantation

BORIS DOI:

10.48350/163205

URI:

https://boris.unibe.ch/id/eprint/163205

Actions (login required)

Edit item Edit item
Provide Feedback